NASDAQ:AUPH - Aurinia Pharmaceuticals Stock Price, Forecast & News

Aurinia Pharmaceuticals trades on the NASDAQ under the ticker symbol "AUPH."

Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) issued its quarterly earnings results on Thursday, November, 14th. The biotechnology company reported ($0.21) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.19) by $0.02. The biotechnology company earned $0.23 million during the quarter, compared to analyst estimates of $0.05 million. Aurinia Pharmaceuticals had a negative net margin of 19,483.96% and a negative return on equity of 50.79%. View Aurinia Pharmaceuticals' Earnings History.

Aurinia Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, March 17th 2020. View Earnings Estimates for Aurinia Pharmaceuticals.

8 Wall Street analysts have issued 12-month price objectives for Aurinia Pharmaceuticals' stock. Their forecasts range from $11.00 to $32.00. On average, they anticipate Aurinia Pharmaceuticals' share price to reach $22.29 in the next twelve months. This suggests a possible upside of 23.5% from the stock's current price. View Analyst Price Targets for Aurinia Pharmaceuticals.

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aurinia Pharmaceuticals in the last year. There are currently 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Aurinia Pharmaceuticals.

News coverage about AUPH stock has been trending very negative on Tuesday, InfoTrie Sentiment reports. The research group rates the sentiment of press coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Aurinia Pharmaceuticals earned a news impact score of -3.0 on InfoTrie's scale. They also assigned news coverage about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View News Stories for Aurinia Pharmaceuticals.

Aurinia Pharmaceuticals saw a increase in short interest in the month of January. As of January 31st, there was short interest totalling 5,830,000 shares, an increase of 6.0% from the January 15th total of 5,500,000 shares. Based on an average trading volume of 3,420,000 shares, the short-interest ratio is currently 1.7 days. Currently, 7.0% of the company's stock are short sold. View Aurinia Pharmaceuticals' Current Options Chain.

Some companies that are related to Aurinia Pharmaceuticals include Jazz Pharmaceuticals (JAZZ), Dr.Reddy's Laboratories (RDY), ACADIA Pharmaceuticals (ACAD), Ascendis Pharma A/S (ASND), The Medicines (MDCO), Horizon Therapeutics (HZNP), Amarin (AMRN), Reata Pharmaceuticals (RETA), United Therapeutics (UTHR), BridgeBio Pharma (BBIO), Evotec (EVTCY), Global Blood Therapeutics (GBT), FibroGen (FGEN), Nektar Therapeutics (NKTR) and GW Pharmaceuticals PLC- (GWPH).

Based on aggregate information from My MarketBeat watchlists, some companies that other Aurinia Pharmaceuticals investors own include Tetraphase Pharmaceuticals (TTPH), NVIDIA (NVDA), Advanced Micro Devices (AMD), Cara Therapeutics (CARA), Micron Technology (MU), Array Biopharma (ARRY), Exelixis (EXEL), Novavax (NVAX), Corbus Pharmaceuticals (CRBP) and Synergy Pharmaceuticals (SGYP).

Aurinia Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional investors include FMR LLC (7.18%), Point72 Asset Management L.P. (3.22%), Franklin Resources Inc. (1.19%), Perceptive Advisors LLC (0.64%), Goldman Sachs Group Inc. (0.56%) and Renaissance Technologies LLC (0.52%).

AUPH stock was sold by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., Franklin Resources Inc., Victory Capital Management Inc., SG Americas Securities LLC, Patriot Financial Group Insurance Agency LLC, Bank of Montreal Can, Ironwood Investment Management LLC and ProShare Advisors LLC.

AUPH stock was bought by a variety of institutional investors in the last quarter, including FMR LLC, Point72 Asset Management L.P., Perceptive Advisors LLC, Renaissance Technologies LLC, Ikarian Capital LLC, Broadfin Capital LLC, Crawford Lake Capital Management LLC and Schonfeld Strategic Advisors LLC.

Shares of AUPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of AUPH stock can currently be purchased for approximately $18.04.

Aurinia Pharmaceuticals has a market capitalization of $2.02 billion and generates $460,000.00 in revenue each year. The biotechnology company earns $-64,120,000.00 in net income (profit) each year or ($0.76) on an earnings per share basis. Aurinia Pharmaceuticals employs 39 workers across the globe.View Additional Information About Aurinia Pharmaceuticals.

The official website for Aurinia Pharmaceuticals is http://www.auriniapharma.com/.

Aurinia Pharmaceuticals' mailing address is 1203-4464 MARKHAM STREET, VICTORIA A1, V8Z 7X8. The biotechnology company can be reached via phone at 250-744-2487 or via email at [email protected]